Most evidence indicates that pharmacological inhibition of ANO1 channel activity may have the potential to provide therapeutic benefits to HNSCC, ESCC, GIST, breast and prostate cancer patients. This evidence concerns the gene ANO1 and gastrointestinal stromal tumor.